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Abstract
Background: As the most stable and experimentally accessible epigenetic mark, DNA methylation is of great interest
to the research community. The landscape of DNA methylation across tissues, through development and in disease
pathogenesis is not yet well characterized. Thus there is a need for rapid and cost effective methods for assessing
genome-wide levels of DNA methylation. The Illumina Infinium HumanMethylation450 (450K) BeadChip is a very
useful addition to the available methods for DNA methylation analysis but its complex design, incorporating two
different assay methods, requires careful consideration. Accordingly, several normalization schemes have been
published. We have taken advantage of known DNA methylation patterns associated with genomic imprinting and
X-chromosome inactivation (XCI), in addition to the performance of SNP genotyping assays present on the array, to
derive three independent metrics which we use to test alternative schemes of correction and normalization. These
metrics also have potential utility as quality scores for datasets.
Results: The standard index of DNA methylation at any specific CpG site is β = M/(M+ U + 100) where M and U are
methylated and unmethylated signal intensities, respectively. Betas (βs) calculated from raw signal intensities (the
default GenomeStudio behavior) perform well, but using 11 methylomic datasets we demonstrate that quantile
normalization methods produce marked improvement, even in highly consistent data, by all three metrics. The
commonly used procedure of normalizing betas is inferior to the separate normalization of M and U, and it is also
advantageous to normalize Type I and Type II assays separately. More elaborate manipulation of quantiles proves to
be counterproductive.
Conclusions: Careful selection of preprocessing steps can minimize variance and thus improve statistical power,
especially for the detection of the small absolute DNA methylation changes likely associated with complex disease
phenotypes. For the convenience of the research community we have created a user-friendly R software package
called wateRmelon, downloadable from bioConductor, compatible with the existing methylumi, minfi and IMA
packages, that allows others to utilize the same normalization methods and data quality tests on 450K data.
Background
As the most stable and experimentally accessible epi-
genetic mark, DNA methylation is of great interest to
the epigenetics research community. The methylomic
landscape across tissues, through development, and in
disease pathogenesis is not yet well characterized, but a
fast-growing field is exploring this methylomic vari-
ation. Illumina has recently developed the Infinium
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HumanMethylation microarray assay, which offers a
cost-effective, high throughput method for quantitatively
assessing methylation across the genome. The initial
HumanMethylation27 (27K) BeadChip interrogated
27,578 CpG sites associated with 14,495 protein-coding
gene promoters [1]. The more recent HumanMethyla-
tion450 (450K) BeadChip assays DNA methylation at
482,421 CpG sites, including 90% of the sites on the
27K array [2,3]. Both platforms quantify DNA methy-
lation at single base resolution by genotyping sodium
bisulfite treated DNA. The bisulfite-converted DNA is
subjected to a whole-genome amplification step, fol-
lowed by fragmentation and hybridization to probes on
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the microarray. Following hybridization, allele-specific
single-base extension of the probes incorporates a fluo-
rescent label (ddNTP) for detection. For both BeadChips
the customary index of DNA methylation fraction at a
specific CpG site is calculated as β = M/(M + U + α)
where M and U are methylated and unmethylated sig-
nal intensities and α is an arbitrary offset (usually 100)
intended to stabilize β values where fluorescent intensi-
ties are low. An alternative index not bounded by 0 and
1 is M = log2((M + α)/(U + α)), which is essentially
equivalent to a logit transformation of β [4].
Infinium humanmethylation beadchip design
In the 27K BeadChip, each CpG site is targeted by two
50 bp probes: one designed to specifically hybridize to the
methylated CpG site (M); and the other to the unmethy-
lated CpG site (U). At each CpG site single-base extension
generates the same color signal for both the M and U
probe. The probe design relies on the assumption that any
CpG sites underlying the probe aremethylated to the same
extent as the target site.
The 450K BeadChip [2,3] achieves increased cover-
age by utilising two different probe types on each array:
Infinium I (n=135,501) and Infinium II (n=350,076)
probes. The Type I probes are the same design as the
probes used in the 27K BeadChip, described above. The
new Type II probes use just one probe per CpG locus, and
employ different dye colors (green and red) to differenti-
ate between M and U signals, respectively. The design of
the Type II probes also avoids the assumption that adja-
cent CpG sites underlying the probe are methylated to the
same extent as the target CpG site by including degener-
ate (R) bases at CpG sites. However the Type II probes can
only include amaximum of three R bases, so Type I probes
are used to assay regions of the DNA with a high density
of CpG sites (for example, promoter CpG islands).
Background
Our approach to analysis of microarray data is to try to
maximize sensitivity for detection of differences between
experimental groups, and accuracy of estimation of abso-
lute methylation fraction is, if anything, secondary. In this
view biases such as background are not in themselves a
problem and indeed attempts to correct them, for example
by subtraction of estimates derived from control probes,
are undesirable because they introduce another source
of variance.
The inclusion of two different types of chemical assay on
the same array poses potential problems for data prepro-
cessing and analysis: preprocessing methods may perform
differently for the two assays; and differing distributions
may make overall rankings of differentially methylated
probes inaccurate. Density plots of the raw β values
confirm that Type I and Type II probes have different
distributions (Figure 1). One of our objectives is therefore
to equalize this difference. Dedeurwaerder et al [5] found
that this reflected a difference in performance between
the two probe types and devised a custom transformation
of the Type II β values to accommodate it. In the density
plot of raw β values (Figure 1), the two peaks of the Type II
probes (representing methylated and unmethylated CpG
sites) are compressed toward β = 0.5. Our insight is that
a higher background in the Type II assays would explain
such a difference in distribution of β values, because it
inflates both M and U. This may be related to systematic
differences in probe design such as GC content or degen-
erate bases, or the fact that background signal results
from two colors in Type II probes and only one in Type I
probes. This is also an example of how manipulations of
the raw intensity can be much simpler than manipulations
of β orM, which have complex distributions.
A number of research groups have developed prepro-
cessing methods to accommodate the differences in signal
between the two probe types [5-7]. Here, we present addi-
tional preprocessing methods to address the difference
between probe types and compare our custom methods
with existing methods in the literature. Our methods all
operate on raw intensities and output β values, which can
be easily transformed toM if required.
Normalization
For the 450K Infinium HumanMethylation450 BeadChip
microarray the manufacturer’s GenomeStudio software
calculates βs from raw intensities and under default
settings performs no normalization, presumably on the
grounds that because the β readout has the total intensity
in the denominator it should be insensitive to system-
atic differences in fluorescent intensity between samples.
The β values are indeed fairly stable and the basic anal-
ysis method works well, particularly for the detection of
large differences, for example between tissues or tumor-
normal pairs [8]. However, for the investigation of sub-
tle differences, such as those seen in common complex
disorders such as schizophrenia [9,10] and diabetes [11],
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Figure 1 Example of density distribution of β values profiled
using Type I and Type II probes.
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there is a need to ensure maximum sensitivity to detect
differential DNA methylation.
A pragmatic approach to the limitations of simple ratio-
based methods to calculate DNA methylation values,
common in the literature [12], has been to quantile nor-
malize β scores. Quantile normalization (QN) is a well
established technique in gene expression analysis, where it
has been shown to perform well [13]. For microarray data
from multiple samples formatted as a matrix with one
column per sample and one row per feature, QN is a non-
linear transformation that replaces each intensity score
with the mean of the features with the same rank from
each array. It is guaranteed to produce identical array-
wide distributions from any data, but whether this can be
achieved without losing information depends on whether
the raw distributions are suitable. A potential weakness of
QN is that in parts of the distribution with few values (and
therefore relatively large interquantile differences), it may
introduce considerable changes. The danger is that these
large changes could increase the variance across samples
for individual features, rather than reducing it as desired.
Performance metrics
The suitability of QN for DNA methylation data has
been assumed based on experience in the analysis of
gene expression data, but there has been little system-
atic testing. Previous DNA methylation data analysis
methods have been assessed using the DNA methyla-
ton differences between experimental groups verified
using an independent method [5]. This has the potential
to be misleading as an unknown portion of the differ-
ences are artefacts. Although normalization operations
manipulate the distribution of values from each sample,
tests of distribution similarity between technical repli-
cates(for example the Kolmogorov-Smirnov test used by
Maksimovic et al [6]) are also potentially misleading
because samples can be identically distributed but uncor-
related. Profile correlations are also insensitive to the
potential problems of normalization because they are
dominated by the majority of probes which do not show
true differences, i.e. the majority of CpG sites assayed
are in a fully methylated or fully unmethylated state
and would change little after normalization, whilst the
minority of intermediate methylation values would be
susceptible to far greater changes after normalization but
would be overlooked by a correlation test [14]. Because
the desired result of normalization is to remove system-
atic errors between samples, the disappearance of batch
effects is a useful indicator [12], but not sufficient as a per-
formance indicator because it does not indicate whether
true differences can still be detected. Clearly there is a
need for methods that directly measure performance to
predict the ability to detect true DNA methylation differ-
ences between samples. Standard, specially constructed
control datasets produced by spiking samples have been
influential in the gene expression field [13], but would not
be as suitable for analysis of DNA methylation.
For DNA methylation we are fortunate in having nat-
ural controls: sites with a clear expectation of a defined
partial methylation level. The first of these is provided
by genomic imprinting. Imprinted genes are expressed
monoallelically depending on parental origin, marked
by allele-specific parent-of-origin dependent methylation
at discrete imprinted differentially methylated regions
(iDMRs). Stable iDMRs have been characterized for
25 human imprinting regions [15,16] and where array
features overlap these, we would expect monoallelic
(therefore 50% (β=0.5)) methylation.
The 450K BeadChip also features 65 control probes
which assay highly-polymorphic single nucleotide poly-
morphisms (SNPs) rather than DNA methylation. These
are included on the array to allow sample quality control
to check for relatedness between individuals and enable
the detection of potential sample mix-ups. The signal
from these probes is expected to cluster into three distinct
groups (representing the heterozygous and two homozy-
gous groups). Although these are not DNA methylation
signals, they could be used to provide an indication of the
degree of technical variance between samples.
Finally, the phenomenon of X-chromosome inactivation
(XCI) provides a second set of loci demonstrating pre-
dictable patterns of DNA methylation. In females, one
copy of the X-chromosome is predominantly inactivated
and largely methylated. Because the level of DNA methy-
lation across active X-chromosome sites varies, we do not
expect uniform X-chromosome hemi-methylation. We
do, however, expect male-female differences, with females
showing at least 50% methylation at CpG sites on the
X-chromosome that are influenced by XCI, and males
substantially less.
Armed with these potential performance metrics and
some ideas about appropriate preprocessing and normal-
ization approaches, we set out to optimize and test nor-
malization using 11 unpublished datasets (total n=696),
from our own ongoing research program (described in
detail in Additional file 1).
Results and discussion
In our ongoing work we have produced 11 450K datasets
comprising samples from whole blood and four brain
regions obtained from over 150 different individuals (total
n=696). In exploring the data we identified and excluded a
small number (less than 1%) of individual samples which
were clearly technical failures based on criteria including
atypical raw intensity distribution and poor correlation
of β with other samples. Conscious of the need to min-
imize technical variation within datasets while retaining
as much information as possible, we then explored three
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sets of probes which we expected to provide performance
metrics that could be used to evaluate processing and nor-
malization methods: probes in iDMRs, SNP probes, and
CpG sites on the X-chromosome.
Performance metrics
Imprinted differentiallymethylated regions
There are 237 probes on the array that lie within a con-
servative set of defined iDMRs [16], and have an expected
β value of 0.5 because they are uniparentally methy-
lated in most tissues. From each dataset we observe a
distribution of β for these probes with a single peak at
approximately 0.5, as expected. QN produces a slightly
narrower peak visible on a density plot (Figure 2a), indi-
cating that we can detect a reduction in inter-sample
variance. As a quantitative measure of this we derive a
value resembling a standard error by dividing the standard
deviation of the full set of DMR β values for the dataset by
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Figure 2 Density plots of the β values generated from the raw and dasen preprocessing methods for Type I and II probes. Plots represent
the loci investigated in each of the three performance tests: a DMRSE, b GCOSE, and c Seabird. Black line=raw, red line=dasen.
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the square root of the number of samples. This measure
was chosen because it is reasonably independent of the
size of the dataset and it should directly predict sensitivity
to detect true differences between groups. We will refer to
this metric as the ‘DMRSE’ (i.e. Differentially Methylated
Regions Standard Error).
SNP probes
There are 65 probes on the 450K BeadChip which assay
highly polymorphic SNPs rather than CpG sites. As
expected the β values for these sites cluster into three
groups, depending on whether the samples are heterozy-
gous, or homozygous at each SNP (see Figure 2b). We
used k-means clustering to partition the observations into
these three clusters and for each SNP returned the sum of
squares and number of samples per cluster. For each SNP
ideal performance (absence of technical variance) would
result in zero-width peaks (i.e. sum of squares = 0). To cap-
ture this across multiple probes, we summed the 65 sum
of squares and then summed the 65 number of samples
per cluster (AA, AB, BB). Next we divided the summed
sum of squares by the summed number of samples. In
order to give a standard-error like metric we then divided
these three mean-square values by the square root of the
total number of samples. Finally, to simplify interpreta-
tion we combined these three measures into a single value
by taking the mean, and refer to this metric as ‘GCOSE’
(Genotype Combined Standard Error).
X-Chromosome
The inactive X-chromosome in females is hypermethy-
lated, and the 11,232 X-chromosome features annotated
for the array show a distinctive β value distribution, once
again centred on approximately 0.5, compared to the
biphasic distribution of autosomal probes. In Cohort 1Ai
for example, a t-test of each probe for sex differences
gives 9,796 significant at the p=0.05 level (Bonferroni cor-
rected for 485,577 tests), of which 8,969 correspond to X-
chromosome loci. The sex difference test with this cut-off
thus recovers 80% of the X-chromosome probes. 91% of
the recovered differences are in X-chromosome loci. True,
autosomal sex-specifically methylated loci are very small
in number and potentially represent autosomal probes
mapping to sequences on the sex-chromosome [17]. We
can therefore conduct a Receiver Operating Characteristic
(ROC) analysis, using the t-test p-value for sex difference
as a predictor of X-chromosome location. The area under
the curve (AUC) provides an estimate of the performance
of the predictor that ranges from 0.5 for an equal chance
to 1 for a perfect predictor (see Figure 2c). In order to
have a metric that goes in the same direction as DMRSE
and GCOSE (i.e. smaller as performance improves), we
use 1−AUC as our metric, which we have named ‘Seabird’
(named after the auk and also the mythical bird roc).
Preprocessing and normalization method design
Given the vast number of potential normalization and pre-
processing methods, we limited our exploration to meth-
ods for which there is a rationale. The naming convention
used for the different preprocessing methods is explained
in full detail in Table 1. Several insights, derived from
data exploration and experience, underlie our selection
of methods to implement and test using the performance
metrics. The first is that the primary data is methylated
Table 1 Table summarising nomenclature of preprocessingmethods
Background adjustment Between-array normalization Dye bias correction
naten n t n
nanet n n t
nanes n n s
danes d n s
danet d n t
danen d n n
daten1 d t n
daten2 d t n
nasen n s n
dasen d s n
We have used a naming convention that encodes key aspects of each method. Vowels were added between the letters for ease of pronunciation.
The 1st letter (column 1) indicates whether background adjustment was performed (i.e. the offset between Type I and II probe intensities added to Type I intensities),
with ‘d’ indicating background adjustment and ‘n’ indicating no background adjustment. Note daten2 is identical to daten1 but with the addition of a linear model of
Sentrix position to obtain smooth background offsets.
The 3rd letter (column 2) specifies whether between-array normalization was performed (i.e. between-sample quantile normalization of M and U separately), with ‘s’
indicating between-array normalization applied to Type I and Type II probes separately, ‘t’ indicating between-array normalization applied to Type I and Type II probes
together and ‘n’ indicating no between-array normalization.
The 5th letter (column 3) specifies whether the dye-bias correction was performed (i.e. quantile normalization of M against U), with ‘s’ indicating dye bias correction
applied to Type I and Type II probes separately, ‘t’ indicating dye bias correction applied to Type I and Type II probes together and ‘n’ indicating no dye bias correction.
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and unmethylated fluorescent intensities (M and U) and
technical variation is likely to be more simply dealt with
by adjusting these, rather than the derived β value, where
effects may be complicated by their interaction. A fur-
ther consideration here is the known potential of QN
to impose large changes in those parts of a distribution
with few members, which in the biphasic β distribution
includes the potentially most interesting central part of
the distribution (β= 0.5). Therefore in addition to test-
ing the raw β values (raw) and QN of βs (betaqn), we
tested βs calculated from separately quantile normalized
M and U (naten) (this method was introduced by Sun et
al [12]). It could also be advantageous to separate Type I
and II probes for QN (compare nasen, dasen with naten,
daten1). M and U distributions differ, and so these should
only be forced to the same distribution with caution, but
quantile normalizing M and U against each other would
have the advantage of removing dye bias variation, which
is a potential problem with Type II assays, so this was
performed in four methods (nanet, nanes, danes, danet).
Type I and Type II probes perform differently. This is
not in itself a normalization issue, but it may be advan-
tageous to minimize the differences so that the rank-
ing of potential differentially methylated loci is more
accurate [5]. This is achieved most simply by adjust-
ing the background difference between Type I and II
probes for both M and U intensities (danes, danet, danen,
daten1, daten2, dasen). Both methylated and unmethy-
lated raw intensities display a characteristic peak close
to zero, which differs slightly between Type I and II
probes (Additional file 2). We use the position of this peak
to calculate the background difference (offset) between
Type I and Type II probes, and we add it to Type I
intensities. Note that we do not aim to eliminate the
background signal, we only seek to equalize the back-
ground signal between Type I and Type II probes.
Because we observed a gradient in background in some
datasets we implemented an optional linear model of
Sentrix position to obtain smooth background offsets.
Once again this procedure is not intended to remove
the background gradient from the raw intensities, this is
accomplished by subsequent QN. The objective is solely
to avoid introducing additional noise while equalizing
background.
Qualitative observations on preprocessing and
normalization
Metrics for each of the methods on one example dataset
calculated separately for Type I and Type II probes are
shown graphically in Figure 3. The first observation is
that according to the standard error measures DMRSE
and GCOSE, Type II probes perform better than Type
I probes across most methods and Type I probes are
more stable than Type II probes. Methods that do not
use any normalization (raw and Fuks [5]) clearly per-
form worse for both types than those that do. Nor-
malizing M and U is clearly better than normalizing β
(compare naten with betaqn). Background adjustment
does not introduce noticeable extra variance (compare
raw with danen). Furthermore, QN of Type I and Type
II intensities separately appear to reduce variance, par-
ticularly for the iDMR measures (compare daten1 and
dasen), but more complicated segmented QN schemes
seem to be counterproductive despite embodying valu-
able insights about the properties of the assay (compare
Tost [7] and SWAN [6] with dasen). Similar graphs of
the three metrics for all of the datasets are presented in
Additional files 3, 4 and 5.
Systematic ranking of methods based onmetrics
The test metrics were subsequently used to quantitatively
determine the best performing preprocessing method
(also see Additional files 3, 4, 5 and 6) using the ap-
proach detailed below and illustrated in Additional file 7.
For each dataset and for Type I and Type II probes sepa-
rately:
A. Calculate the metric scores (DMRSE, GCOSE_AA,
GCOSE_AB, GCOSE_BB, Seabird) for each of the 15
preprocessing methods (raw. . . swan)
B. For each preprocessing method take the mean of
three SNP scores calculated in [A] (i.e. GCOSE_AA,
GCOSE_AB, GCOSE_BB) to generate just one SNP
score (GCOSE)
C. For each of the three metrics [B] rank the
preprocessing methods
D. For each of the preprocessing methods calculate the
mean of the three ranked metrics [C]
E. For each preprocessing method calculate the mean of
mean ranks [D] across the datasets, for Type I and
Type II probes separately.
F. Rank the mean of metric values across all datasets [E]
to generate a final score representing the
performance of each of the 15 preprocessing
methods (Table 2).
Using this approach, our data indicates that dasen is
the best performing method across both probe types
(Table 2). This method involves background adjustment
of the methylated and unmethylated intensities. This is
followed by separate QN of methylated Type I, unmethy-
lated Type I, methylated Type II and unmethylated Type II
intensities.
It is evident from the quantitative ranking method
(Table 2) and figures for each individual dataset
(Additional files 3, 4 and 5) that the dasen method
performs consistently well for both the Type I and
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a b c
Figure 3 Results of the performance tests for Cohort 1C. All values range between 0 and 1. Lower values are indicative of a more sensitive
preprocessing method. :a) DMRSE (x10−3), b) GCOSE (x10−4) and c) Seabird (x10−2). Type I probes are denoted by circles and Type II probes by
triangles.
Type II probe data. Figure 2 displays the β values
for one dataset before and after preprocessing with
the dasen method, with the density distribution of
Type I and Type II probes plotted both together and
separately.
Figure 2a shows that the dasen method decreases
the standard error across CpG sites within iDMRs, as
expected (DMRSE test). Figure 2b displays the density
distribution of the signal from the SNP probes (GCOSE
test). While the difference in peak width is not read-
ily visible at this scale, the effect of background adjust-
ment on Type I probes is clearly visible. Figure 2c
shows the ROC curve of true positives and false posi-
tives for predicting X-chromosome location (Seabird test).
An increased area under the curve indicates improved
sensitivity to detect these differences. The data is much
improved for the Type II probes, which represent 72%
of the probes on the array. For Cohort 1Ai for exam-
ple, dasen gives us 296 (3%) additional sex differ-
ences at the Bonferroni-corrected p <.05 level, compared
to raw.
Limitations
We propose three metrics of data homogeneity that
evaluate different and substantial parts of the array.
For the datasets we use these give a clear picture about
the optimal quantile-based normalization procedure. The
possibility remains that these metrics miss some aspect of
performance. We have also used a large number of exper-
imental datasets across multiple tissues, but there may
be datasets with substantially different properties that
require different handling. In particular, we have only ana-
lyzed relatively homogeneous datasets derived from brain
or whole blood. There may be more drastic variation in
cultured cells or tumors, and we have also not extensively
addressed normalization of datasets containingmore than
one tissue type. We expect that beyond a certain level of
heterogeneity, QN procedures will be counterproductive.
Our approach would be useful in evaluating this. Finally
we have only tested methods based on QN. Although
there is a strong consensus in favour of this method, it is
possible that a different approach based, for example, on
scaling, could possibly work better.
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Table 2 Overall rank scores of each preprocessingmethod
TypeI TypeII Average
raw 6.5 11 8.75
betaqn 14 13 13.5
naten 12 9 10.5
nanet 11 3 7
nanes 9.5 7.5 8.5
danes 2.5 7.5 5
danet 1 6 3.5
danen 5 12 8.5
daten1 4 4 4
daten2 8 5 6.5
nasen 9.5 1.5 5.5
dasen 2.5 1.5 2
fuks 6.5 15 10.75
tost 13 14 13.5
swan 15 10 12.5
Ranks calculated from the three performance metrics applied to 11 datasets.
Ranks are shown for Type I and Type II probes separately as well as averaged
across both probe types. Dasen is shown to be the best preprocessing method
across both probe types.
Future directions
Rather than attempting to sample the entire universe of
experiments done with this array ourselves, we are dis-
tributing what we hope is a convenient software frame-
work to allow others to make similar tests. We do not
advocate selecting or creating a custom normalization for
each dataset, but it is important to find out if there are
cases where the apparent best method fails.
We have implemented our functions with a simple, con-
sistent interface that takes matrices of methylated and
unmethylated intensities or β or M values. The source
code and analysis scripts using them can be found in
Additional file 8. For the convenience of users we have
also created an object-oriented R software package called
wateRmelon, available to download from bioConductor.
In this package all of the functions mentioned above are
default methods for generic functions of the same name
that understand objects from the existing methylumi
[18], minfi [19], and IMA [20] packages. The output from
normalization methods is β values, but these can be
conveniently transformed to M values using the beta2m
function in the wateRmelon package.
While this work was under review, an alternative
method of equalizing type I and II assay performance
by applying a mixture modelling approach to β was
published [21]. We have made the method available in
the wateRmelon package. While computationally expen-
sive, this method could potentially improve on the peak
correction [5] or our background equalization method,
and this could be investigated further.
Conclusions
Currently the DNA methylation field resembles gene
expression studies of a decade ago: it is technology-
limited and characterized by small sample sizes, diverse
techniques and variable statistical standards [22].
Fortunately the field can benefit from the development
work invested over the last ten years in gene expres-
sion and genotyping technology, and we can quickly
develop and test sophisticated analysis methods. We have
used 11 datasets to investigate 15 different methods of
correction and normalization. We then evaluated
each method using features on the array that assay
known sites of differential methylation or genotype.
The results of our tests reveal that a combination
of background adjustment and between-array quan-
tile normalization is optimal for data processing, to
allow the detection of differential methylation between
samples.
Methods
Samples
11 datasets were used to evaluate our preprocess-
ing pipeline (Additional file 1). Seven of the datasets
were obtained from one cohort of post-mortem
brain samples from the MRC London Brain Bank for
Neurodegenerative Diseases (http://www.kcl.ac.uk/iop/
depts/cn/research/mrclondonbrainbank.aspx): cerebel-
lum (1Ai) (n=91), rescan of cerebellum data (1Aii)
(n=36), frontal cortex (1B) (n=89), entorhinal cortex
(1C) (n=93), superior temporal gyrus (1D) (n=94), whole
blood (1E) (n=95), frontal cortex and entorhinal cortex
(1BC) (n=46), cerebellum and superior temporal gyrus
(1AD) (n=47). Two of the datasets were obtained from
a separate cohort from the London Brain Bank for Neu-
rodegenerative Diseases: cerebellum (2A) (n=42), frontal
cortex (2B) (n=43). The final dataset was obtained from
DNA from the Autism Tissue Program (http://www.
autismtissueprogram.org/): cerebellum (3A) (n=18).
450Kmethylation beadchip analysis
500 ng of genomic DNA from each sample was
treated with sodium bisulfite in duplicate, using the
EZ96 DNA methylation kit (Zymo Research, CA,
USA) following the manufacturer’s standard protocol.
Genome-wide DNA methylation was assessed using
the Illumina Infinium HumanMethylation450 BeadChip
(Illumina Inc, CA, USA) according to manufacturer’s
instructions. Illumina GenomeStudio software was used
to extract the raw signal intensities of each probe
(without background correction or normalization).
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Statistical analysis
All computations and statistical analyses were per-
formed using R 2.15.0 [23] and Bioconductor 2.12 [24].
Signal intensities were imported into R using the methy-
lumi package [18] as a methylumi object. Initial qual-
ity control checks were performed using functions in
the methylumi package to assess concordance between
reported and genotyped gender. Non-CpG SNP probes on
the array were also used to confirm that multiple tissues
were sourced from the same individual where expected.
Comparative analysis was performed using R scripts pro-
vided in Additional file 8. For the convenience of users
we have also packaged the functions into an R pack-
age: wateRmelon, which is available from the bioCon-
ductor repository from version 2.12 (for R version 3.0
and higher). The functions in the package are all generic
and methods are provided for the objects produced by
the packages methylumi [18], minfi [19], and IMA [20],
as well as wrappers for the methods of Dedeurwaerder
et al [5] A number of packages from CRAN and
bioConductor were used: quantile normalization using
limma [25]; data handling using methylumi [18] and minfi
[19]; and performance assessment using ROCR [26]. All
of the data used in this publication has been deposited in
GEO (series accession GSE43414).
Ethical approval
Epigenomic profiling on post-mortem brain tissue was
approved by the UK National Health Service (NHS)
National Research Ethics Service (NRES) (reference num-
ber: 10/H0808/114). Tissue obtained from the Medical
Research Council (MRC) Brainbank for Neurodegerative
Diseases was consented fully prior to death and approved
by the NHS RES (reference number: 08/MRE09/38). The
Human Tissue Authority (HTA) license number for the
brain bank is 12293.
Additional files
Additional file 1: Summary of cohorts used in this study.
Additional file 2: Density plots of the methylated (M) and
unmethylated (U) raw signal intensities. Type I and II probes plotted
separately, with maximum signal peak heights represented by dotted lines.
Horizontal red line represents offset between the maximum peak height of
probe Types I and II. The offset is added to Type I assay intensities to
equalize background in the methods whose names begin with ‘d’.
Additional file 3 : Results of the DMRSE performance tests for all
remaining datasets (x10-3 scale is used on the y-axis). Lower values are
indicative of a more sensitive preprocessing method. Type I probes are
denoted by circles and Type II probes by triangles.
Additional file 4: Results of the GCOSE performance tests for all
remaining datasets (x10-4 scale is used on the y-axis). Lower values are
indicative of a more sensitive preprocessing method. Type I probes are
denoted by circles and Type II probes by triangles.
Additional file 5: Results of the Seabird performance tests for all
remaining datasets (x10-2 scale is used on the y-axis). Cohort 3A is
absent because all samples were male, making the Seabird test redundant.
Lower values are indicative of a more sensitive preprocessing method.
Type I probes are denoted by circles and Type II probes by triangles.
Additional file 6: Results of the GCOSE performance tests split by
genotype group for all datasets (x10-4 scale is used on the y-axis).
Lower values are indicative of a more sensitive preprocessing method.
Type I probes are denoted by circles and Type II probes by triangles. This
shows that the relative performance of our custom methods perform
consistently across the range of betas, and that the tost method performs
worst in the mid-range while swan does worst at the extremes.
Additional file 7: Illustration of method ranking procedure.
Additional file 8: Source code and analysis scripts used in this paper
and the wateRmelon R package.
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